These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 3055690)

  • 21. Chemotherapy for colorectal carcinoma: observations regarding recent clinical trials using biochemical modulation.
    Wadler S; Schwartz EL
    J Clin Oncol; 1995 Oct; 13(10):2676-7. PubMed ID: 7595721
    [No Abstract]   [Full Text] [Related]  

  • 22. Sequential chemotherapy with methotrexate and 5-fluorouracil: mechanism of synergistic effect.
    Kanamaru R; Kakuta H; Sato T; Ishioka C; Konishi Y; Ishikawa A; Asamura M; Wakui A
    Sci Rep Res Inst Tohoku Univ Med; 1986 Dec; 33(1-4):1-8. PubMed ID: 2442810
    [No Abstract]   [Full Text] [Related]  

  • 23. 2006 - the year in review.
    Chu E
    Clin Colorectal Cancer; 2006 Nov; 6(4):256-7. PubMed ID: 17241508
    [No Abstract]   [Full Text] [Related]  

  • 24. 5-Fluorouracil and mitomycin-C in colorectal cancer: unacceptable conclusion.
    Herrmann R
    Ann Oncol; 1998 Mar; 9(3):342. PubMed ID: 9714583
    [No Abstract]   [Full Text] [Related]  

  • 25. 5-Fluorouracil and mitomycin-C in colorectal cancer: unacceptable conclusion.
    Herrmann R
    Ann Oncol; 1998 Feb; 9(2):230. PubMed ID: 9553673
    [No Abstract]   [Full Text] [Related]  

  • 26. Can we individualize chemotherapy for colorectal cancer?
    Chan R; Kerr DJ
    Ann Oncol; 2004 Jul; 15(7):996-9. PubMed ID: 15205190
    [No Abstract]   [Full Text] [Related]  

  • 27. Therapeutic doses of dipyridamole failed to potentiate 5-fluorouracil tumor activity.
    Kosmidis P; Kozatsani-Halvidi D; Tsaroucha E; Tsavaris N
    J Chemother; 1991 Feb; 3(1):61-3. PubMed ID: 2019867
    [No Abstract]   [Full Text] [Related]  

  • 28. Role of interferon as a modulator of fluoropyrimidines: reply to a recent editorial.
    Wadler S; Schwartz EL
    Ann Oncol; 1997 Feb; 8(2):139-40; discussion 141. PubMed ID: 9093721
    [No Abstract]   [Full Text] [Related]  

  • 29. Highlights from: XII European Cancer Conference, Copenhagen, Denmark, September 21-25, 2003.
    Lee D; Price N; Tyagi P
    Clin Colorectal Cancer; 2003 Nov; 3(3):142-6. PubMed ID: 14706171
    [No Abstract]   [Full Text] [Related]  

  • 30. Is there a standard chemotherapeutic strategy in colorectal cancer?
    Zaniboni A; Meriggi F; Rizzi A; Mutti S; Morandi G
    Crit Rev Oncol Hematol; 1999 May; 30(3):229-38. PubMed ID: 10439068
    [No Abstract]   [Full Text] [Related]  

  • 31. Gastrointestinal cancer: Rationale for metronomic chemotherapy in phase III trials.
    Kerbel RS; Grothey A
    Nat Rev Clin Oncol; 2015 Jun; 12(6):313-4. PubMed ID: 25963090
    [No Abstract]   [Full Text] [Related]  

  • 32. Intraportal 5-fluorouracil for colorectal cancer: the AXIS trial.
    Garten L; Stenning S; Gray R
    Lancet; 1992 Oct; 340(8825):985. PubMed ID: 1357399
    [No Abstract]   [Full Text] [Related]  

  • 33. Explaining the unexplainable: EGFR antibodies in colorectal cancer.
    Grothey A; Lenz HJ
    J Clin Oncol; 2012 May; 30(15):1735-7. PubMed ID: 22473160
    [No Abstract]   [Full Text] [Related]  

  • 34. S-1: another oral agent for patients with colorectal cancer.
    Benson AB
    Lancet Oncol; 2013 Dec; 14(13):1244-5. PubMed ID: 24225156
    [No Abstract]   [Full Text] [Related]  

  • 35. When less is more: maintenance therapy in colorectal cancer.
    Hubbard JM; Grothey A
    Lancet; 2015 May; 385(9980):1808-10. PubMed ID: 25862518
    [No Abstract]   [Full Text] [Related]  

  • 36. Can money really be no object when cancer care is the subject?
    Saltz LB
    J Clin Oncol; 2015 Apr; 33(10):1093-4. PubMed ID: 25691668
    [No Abstract]   [Full Text] [Related]  

  • 37. Translation from clinical trials to routine practice: how to demonstrate community benefit.
    Roder D; Buckley E
    Asia Pac J Clin Oncol; 2015 Mar; 11(1):1-3. PubMed ID: 25628060
    [No Abstract]   [Full Text] [Related]  

  • 38. Balancing Clinical Progress With Economic Sustainability: In Quest of a Courageous Solution.
    Fasola G; Aprile G; Pinto C
    J Clin Oncol; 2015 Nov; 33(32):3841-2. PubMed ID: 26304899
    [No Abstract]   [Full Text] [Related]  

  • 39. Targeted immunotherapy for hairy cell leukemia.
    Park JH; Levine RL
    J Clin Oncol; 2012 May; 30(15):1888-90. PubMed ID: 22355051
    [No Abstract]   [Full Text] [Related]  

  • 40. Colorectal cancer in 2013: Towards improved drugs, combinations and patient selection.
    Schmoll HJ; Stein A
    Nat Rev Clin Oncol; 2014 Feb; 11(2):79-80. PubMed ID: 24445520
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.